European Journal of Gynaecological Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study
In conclusion, patients with primary platinum sensitive disease who received fewer prior lines of chemotherapy were able to receive more cycles of bevacizumab, which was associated with improved overall survival. Survival worsened when bevacizumab was initiated later in the ordinal sequence of therapies.PMID:36874058 | PMC:PMC9980410 | DOI:10.22514/ejgo.2023.002 (Source: European Journal of Gynaecological Oncology)
Source: European Journal of Gynaecological Oncology - March 6, 2023 Category: OBGYN Authors: Talayeh S Ghezelayagh Emily S Wu Emma L Barber Minh D Dao Emese Zsiros Renata R Urban Heidi J Gray Barbara A Goff Chirag A Shah Nikki L Neubauer James Y Dai Janos L Tanyi John B Liao Source Type: research